Madendag Yusuf, Sahin Erdem, Madendag Ilknur Col, Sahin Mefkure Eraslan, Acmaz Gokhan, Karaman Hatice
1 Department of Obstetrics and Gynecology, Health Sciences University Kayseri Education and Research Hospital, Kayseri, Turkey.
2 Department of Obstetrics and Gynecology, Erciyes University Faculty of Medicine, Kayseri, Turkey.
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818783911. doi: 10.1177/1533033818783911.
Progesterone-induced blocking factor, which is released from maternal lymphocytes during pregnancy mediates the immune effect of progesterone. According to new reports, it is suggested that proliferating cells, such as human trophoblasts, mesenchymal stem cells, and malignant tumors, can excrete progesterone-induced blocking factor at high ratio to escape from maternal immunity. It is shown in recent studies that progesterone-induced blocking factor is overexpressed in many malignant tumors such as breast, cervical, lymphoma, and leukemia. There are no data about progesterone-induced blocking factor expression in ovarian cancer cells. Hence, it is aimed to determine the progesterone-induced blocking factor expression levels in epithelial ovarian cancer.
The study which was a retrospective cross-sectional study was conducted in a University Hospital. Twenty tissue specimens of patients with epithelial ovarian cancer and 20 tissue specimens of patients with healthy ovary were included in the study. Primary rabbit polyclonal anti- progesterone-induced blocking factor antibody was used to incubate the sections at a ratio of 1:300.
When the tissue sections were compared based on immunostaining with progesterone-induced blocking factor, we detected high stromal progesterone-induced blocking factor expression in the epithelial ovarian cancer group as check against to the normal ovarian group ( P = .007). Similarly, we found high glandular progesterone-induced blocking factor expression in the epithelial ovarian cancer group as check against to the normal ovarian group ( P < .001).
Proving the existence of progesterone-induced blocking factor expression in epithelial ovarian cancer cells may lead new visions or new studies for epithelial ovarian cancer immunotherapy. As a result, epithelial ovarian cancer cells have greater levels of expression of progesterone-induced blocking factor protein than normal ovarian tissue according to immunohistochemistry. Further research is needed to understand the clinical importance of this finding, to learn outcomes of high levels of progesterone-induced blocking factor, and to investigate its underlying mechanisms.
孕期母体淋巴细胞释放的孕酮诱导封闭因子介导孕酮的免疫效应。根据最新报道，提示增殖细胞，如人滋养层细胞、间充质干细胞和恶性肿瘤细胞，能够以高比例分泌孕酮诱导封闭因子以逃避母体免疫。最近的研究表明，孕酮诱导封闭因子在许多恶性肿瘤中过度表达，如乳腺癌、宫颈癌、淋巴瘤和白血病。目前尚无关于卵巢癌细胞中孕酮诱导封闭因子表达的数据。因此，本研究旨在确定上皮性卵巢癌中孕酮诱导封闭因子的表达水平。
本研究为回顾性横断面研究，在一所大学医院进行。研究纳入了20例上皮性卵巢癌患者的组织标本和20例健康卵巢患者的组织标本。用兔抗人孕酮诱导封闭因子多克隆抗体以1:300的比例孵育切片。
当基于孕酮诱导封闭因子免疫染色对组织切片进行比较时，我们发现上皮性卵巢癌组的基质中孕酮诱导封闭因子表达高于正常卵巢组（P = .007）。同样，我们发现上皮性卵巢癌组的腺体内孕酮诱导封闭因子表达高于正常卵巢组（P < .001）。
证实上皮性卵巢癌细胞中存在孕酮诱导封闭因子表达可能为上皮性卵巢癌免疫治疗带来新的视野或新的研究方向。结果表明，根据免疫组化，上皮性卵巢癌细胞中孕酮诱导封闭因子蛋白的表达水平高于正常卵巢组织。需要进一步研究以了解这一发现的临床重要性，了解高水平孕酮诱导封闭因子的结果，并探究其潜在机制。
